Atlas Trials

A Study to Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

Clinical trial NCT02742519 · TERMINATED

Trial details

NCT number
NCT02742519
Sponsor
Vertex Pharmaceuticals Incorporated
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Cystic Fibrosis
Start date
2016-05-01
Primary completion
2017-08-01
Enrollment
14

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.